Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer.
Shivan SivakumarEnas Abu ShahDavid J AhernEdward H Arbe-BarnesAshwin K JainarayananNagina MangalSrikanth ReddyAniko RendekAlistair EastonElke KurzMichael SilvaZahir SoonawallaLara Rosaline HeijRachael J M Bashford-RogersMark Ross MiddletonMichael L DustinPublished in: Cancers (2021)
Pancreatic cancer has one of the worst prognoses of any human malignancy and leukocyte infiltration is a major prognostic marker of the disease. As current immunotherapies confer negligible survival benefits, there is a need to better characterise leukocytes in pancreatic cancer to identify better therapeutic strategies. In this study, we analysed 32 human pancreatic cancer patients from two independent cohorts. A multi-parameter mass-cytometry analysis was performed on 32,000 T-cells from eight patients. Single-cell RNA sequencing dataset analysis was performed on a cohort of 24 patients. Multiplex immunohistochemistry imaging and spatial analysis were performed to map immune infiltration into the tumour microenvironment. Regulatory T-cell populations demonstrated highly immunosuppressive states with high TIGIT, ICOS and CD39 expression. CD8+ T-cells were found to be either in senescence or an exhausted state. The exhausted CD8 T-cells had low PD-1 expression but high TIGIT and CD39 expression. These findings were corroborated in an independent pancreatic cancer single-cell RNA dataset. These data suggest that T-cells are major players in the suppressive microenvironment of pancreatic cancer. Our work identifies multiple novel therapeutic targets that should form the basis for rational design of a new generation of clinical trials in pancreatic ductal adenocarcinoma.
Keyphrases
- single cell
- end stage renal disease
- regulatory t cells
- poor prognosis
- endothelial cells
- clinical trial
- chronic kidney disease
- rna seq
- ejection fraction
- stem cells
- high throughput
- newly diagnosed
- dendritic cells
- immune response
- dna damage
- transcription factor
- randomized controlled trial
- induced pluripotent stem cells
- genome wide
- peripheral blood
- machine learning
- nk cells
- double blind
- placebo controlled
- phase ii